Browsing Tag
ODYSSEY OUTCOMES trial
1 post
Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission’s (EC) approval of Praluent (alirocumab)…